News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Says Lowering Prices in China Caused Higher Sales



5/22/2013 9:31:54 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

May 21, 2013 -- Want to increase revenues in China? You might try lowering prices. It seems to have worked for GlaxoSmithKline. In 2009, the company reduced the cost of its allergy treatment, Avamys nasal spray. The number of units sold jumped to five times their previous figures, though revenues clearly gained less than that. Overall, GSK’s China revenues were up 20% in 2012, reaching $1.5 billion. More details....

Stock Symbol: (NYSE: GSK)



Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES